nomonoma.de
Comeback der Gentherapie - NomoNoma - die 4. Gewalt
http://www.nomonoma.de/comeback-der-gentherapie
NomoNoma – die 4. Gewalt. No Money – No Manipulation, die Zeit ist reif für eine neue 4. Gewalt im Wissenschaftsjournalismus. Wissenschaft & Forschung. Medizin & Gesundheit. Insider & Whistleblower. Künstliches Blatt imitiert Photosynthese. CAR T – Hype oder Hoffnungsträger. Glyphosat: Wie abhängig sind Experten? Juno: Größtes Biotech-IPO 2014. Monsanto und die Nachlässigkeit von Journalisten. Von der Sicherheit und Wirksamkeit seiner Gentherapie zu überzeugen. Seit den Anfängen der Genetik träumen Wisse...
ir.celladon.com
Board of Directors - Celladon
http://ir.celladon.com/directors.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. President and CEO, Orexigen. Member of the Audit Committee. Chair of the Compensation Committee. Executive Vice President of corporate and medical affairs and chief compliance officer at Gilead Sciences. Member of the Compensation Committee.
ir.celladon.com
Email Alert Subscription - Celladon
http://ir.celladon.com/profile.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. Step 1 of 3: Select Options. Quarterly and Annual Reports. All Events and Presentations. In advance of any event. Unsubscribe from Investor Relations email alerts.
ir.celladon.com
Corporate Governance - Celladon
http://ir.celladon.com/corporate-governance.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. File is in Briefcase. Nominating and Corporate Governance Committee Charter. File is in Briefcase. File is in Briefcase. Code of Business Conduct and Ethics. File is in Briefcase. Add file to Briefcase.
ir.celladon.com
Investor Relations - Celladon
http://ir.celladon.com/index.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Celladon's financial performance into perspective. Mar 21, 2016. Mar 9, 2016.
ir.celladon.com
Committee Composition - Celladon
http://ir.celladon.com/committees.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. President and CEO, Orexigen. Member of the Audit Committee. Chair of the Compensation Committee. Executive Vice President of corporate and medical affairs and chief compliance officer at Gilead Sciences. Member of the Compensation Committee.
ir.celladon.com
Analyst Coverage - Celladon
http://ir.celladon.com/analysts.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. Celladon is covered by the following analysts. Ravi Mehrotra Ph.D. Elemer Prios Ph.D. Brian Klein M.D. Wedbush Pac Grow Life Science. David Nierengarten Ph.D.
ir.celladon.com
Historic Stock Lookup - Celladon
http://ir.celladon.com/stocklookup.cfm
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. Historic Stock Lookup is currently unavailable.
ir.celladon.com
Events & Presentations - Celladon
http://ir.celladon.com/eventdetail.cfm?EventID=159437
Stem Cell Factor (mSCF) Gene Therapy Program. Annual Reports and Proxies. Mar 21, 2016. Celladon Announces Results of Special Meeting. Mar 9, 2016. ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger. 124; Terms and Conditions. Apr 27, 2015.